Apple of the Dermatologist’s Eye

Sebaratnam, Deshan F

doi:10.1001/jamadermatol.2014.3086

Cited by 6 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Discussion | In immunocompetent patients, metastatic melanomas are known for their poor prognosis, which is even worse in immunocompromised organ transplant recipients. 1 New treatment options for metastatic melanoma have been established, leading to a significant improvement in recurrencefree and overall survival. These therapies, especially immunotherapies based on cytotoxic T-lymphocyte-associated protein 4 blockade with ipilimumab 2 and targeted therapies inhibiting BRAF V600E mutations with vemurafenib 3 and dabrafenib, 4 have not been investigated in immunocompromised patients such as lung transplant recipients.…”

Section: Braf Inhibition In a Lung Transplant Recipient With Metastatmentioning

confidence: 99%

“…The rosette is a widely used dermatology descriptor; clinically as in linear IgA disease, dermoscopically as in keratinizing tumors and histologically as in cyclindromas. 1 Chocolates are always a favorite, and chocolate agar is also the desired medium for growth of Mycobacterium chelonae. Champagne is liberally consumed on Valentine's Day, and once the bottle is overturned, it resembles the leg of a patient with advanced lipodermatosclerosis.…”

Section: Braf Inhibition In a Lung Transplant Recipient With Metastatmentioning

confidence: 99%

See 1 more Smart Citation

BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma

et al. 2016

View full text Add to dashboard Cite

and sorafenib therapy was restarted without further sequelae. Unlike other cases reported in the literature, the patient described herein and the one described by Bilaç et al 2 had clinically EM-like eruptions with targetoid lesions, nondiagnostic histopathologic findings, and successful reinitiation of sorafenib treatment. Thus, we recommend biopsy of targetoid eruptions during sorafenib therapy to differentiate between a diagnosis of EM and EM-like sorafenib reaction to minimize discontinuation of an antineoplastic agent shown to prolong progression-free survival.

show abstract

Section: Braf Inhibition In a Lung Transplant Recipient With Metastatmentioning

confidence: 99%

Section: Braf Inhibition In a Lung Transplant Recipient With Metastatmentioning

confidence: 99%

BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma

et al. 2016

View full text Add to dashboard Cite

show abstract

MultipleBRAFWild-Type Melanomas During Dabrafenib Treatment for MetastaticBRAF-Mutant Melanoma

et al. 2015

View full text Add to dashboard Cite

Cutaneous malignant tumors are the most frequent adverse events of BRAF inhibitors; therefore, strict dermatologic surveillance in a referral center aided by digital follow-up is mandatory, especially when multiple nevi are present and these drugs are used in an adjuvant setting. In view of our findings, the pathogenesis of the development of new melanomas seems to be different from therapy resistance. Whether paradoxical RAF activation could explain these BRAF wild-type secondary malignant tumors is still unknown.

show abstract